Ani Pharmaceuticals (ANIP) Short term Debt (2012 - 2026)

Ani Pharmaceuticals has disclosed Short term Debt across 12 years of filings, most recently posting $19.3 million for Q1 2026.

• Short term Debt for Q1 2026 came in at $19.3 million, up 8327.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.3 million (up 8327.07% YoY), and the FY2025 annual result was $17.3 million, up 88.27% from the prior year.
• Short term Debt came in at $19.3 million for Q1 2026 at Ani Pharmaceuticals, up from $17.3 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $25.0 million in Q2 2023 to a low of $229000.0 in Q1 2025.
• The 5-year median for Short term Debt is $850000.0 (2022), against an average of $7.7 million.
• Across the five-year window, Short term Debt tumbled 96.6% in 2024 and jumped 8327.07% in 2026, its largest moves.
• Ani Pharmaceuticals' Short term Debt stood at $850000.0 in 2022, then changed by 0.0% to $850000.0 in 2023, then jumped by 979.06% to $9.2 million in 2024, then surged by 88.27% to $17.3 million in 2025, then advanced by 11.76% to $19.3 million in 2026.
• The last three Short term Debt figures came in at $19.3 million (Q1 2026), $17.3 million (Q4 2025), and $15.2 million (Q3 2025), per Business Quant data.